Journal article
Yttrium 90 ibritumomab tiuxetan in lymphoma
Abstract
Radioimmunoconjugates are radioisotope-bound monoclonal antibodies that target radiation specifically to sites of lymphoma involvement. Initial studies of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma (NHL) have suggested benefit in patients with relapsed or refractory indolent disease. However, the routine adoption of this agent is tempered by concerns of associated toxicities and unclear long-term benefit. A comprehensive search for …
Authors
Cheung MC; Haynes AE; Stevens A; Meyer RM; Imrie K; care TMOTHDSGOTCCOPIE-B
Journal
Leukemia & Lymphoma, Vol. 47, No. 6, pp. 967–977
Publisher
Taylor & Francis
Publication Date
1 2006
DOI
10.1080/10428190600572582
ISSN
1042-8194